#Peptide Therapeutics Market Size & Share | Explore Tumblr posts and blogs

janetushar1 · 3 months ago

Text

Peptide Therapeutics Market to Hit $81.48 Billion by 2032

The global Peptide Therapeutics Market was valued at USD 43.04 Billion in 2024 and it is estimated to garner USD 81.48 Billion by 2032 with a registered CAGR of 7.35% during the forecast period 2024 to 2032.

Global Peptide Therapeutics Market Research Report 2024, Growth Rate, Market Segmentation, Peptide Therapeutics Market. It affords qualitative and quantitative insights in phrases of market size, destiny trends, and nearby outlook Peptide Therapeutics Market. Contemporary possibilities projected to influence the destiny capability of the market are analyzed in the report. Additionally, the document affords special insights into the opposition in particular industries and diverse businesses. This document in addition examines and evaluates the contemporary outlook for the ever-evolving commercial enterprise area and the prevailing and future outcomes of the market.

Get Sample Copy of Report @ https://www.vantagemarketresearch.com/peptide-therapeutics-market-2350/request-sample

** Note: You Must Use A Corporate Email Address OR Business Details.

The Major Players Profiled in the Market Report are:-

Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca PLC (UK), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland)

Peptide Therapeutics Market 2024 covers powerful research on global industry size, share, and growth which will allow clients to view possible requirements and forecasts. Opportunities and drivers are assembled after in-depth research by the expertise of the construction robot market. The Peptide Therapeutics Market report provides an analysis of future development strategies, key players, competitive potential, and key challenges in the industry.

Global Peptide Therapeutics Market Report 2024 reveals all critical factors related to diverse boom factors inclusive of contemporary trends and traits withinside the worldwide enterprise. It affords a complete review of the top manufacturers, present-day enterprise status, boom sectors, and commercial enterprise improvement plans for the destiny scope.

The Peptide Therapeutics Market document objectives to offer nearby improvement to the market using elements inclusive of income revenue, destiny market boom rate. It gives special observation and analysis of key aspects with quite a few studies strategies consisting of frenzy and pestle evaluation, highlighting present-day market conditions. to be. Additionally, the document affords insightful records approximately the destiny techniques and opportunities of worldwide players.

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/peptide-therapeutics-market-2350/0

Global Peptide Therapeutics Market, By Region

1) North America- (United States, Canada, Mexico, Cuba, Guatemala, Panama, Barbados, and many others)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium, and many others)

3) the Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam, and many others)

4) the Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria, and many others)

5) Latin America- (Brazil, Argentina, Colombia, Chile, Peru, and many others)

This Peptide Therapeutics Market Research/analysis Report Contains Answers to your following Questions

What trends, challenges, and barriers will impact the development and sizing of the global market?

What is the Peptide Therapeutics Market growth accelerator during the forecast period?

SWOT Analysis of key players along with its profile and Porter’s five forces analysis to supplement the same.

How much is the Peptide Therapeutics Market industry worth in 2019? and estimated size by 2024?

How large is the Peptide Therapeutics Market? How long will it keep growing and at what rate?

Which section or location will force the market and why?

What is the important thing current tendencies witnessed in the Peptide Therapeutics Market?

Who are the top players in the market?

What and How many patents are filed by the leading players?

What is our Offering for a bright industry future?

The Research Objectives of this Report are to:-

Company, key regions/countries, merchandise and applications, historical records from 2018 to 2022, and global Peptide Therapeutics Market till 2032. Study and analyze the market length (cost and volume).

To recognize the structure of Peptide Therapeutics Market via way of means of figuring out its numerous subsegments.

Peptide Therapeutics Market on the subject of the primary regions (with every essential country). Predict the cost and length of submarkets.

To examine the Peptide Therapeutics Markets with appreciation to person boom trends, destiny prospects, and their contribution to the general market.

To examine aggressive trends consisting of expansions, contracts, new product launches, and acquisitions withinside the market.

Strategic profiling of key gamers and complete evaluation of growth strategies.

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/peptide-therapeutics-market-2350

Reasons to Buy Market Report

The market record presents a qualitative and quantitative analysis of the market based on segmentation that includes each economic and non-economic element.

Peptide Therapeutics Market through the region. The market evaluation highlights the consumption of products/services in areas and well-known shows elements influencing the market in every region.

Peptide Therapeutics Market. It consists of an in-depth analysis of the market from specific views via Market Porter's Five Forces Analysis and provides insights into the market via the Value Chain.

The Peptide Therapeutics Market file provides an outline of market fee (USD) information for every segment and sub-segment.

It consists of an in-depth analysis of the market from distinct views via a 5 forces analysis of the Peptide Therapeutics Market and offers insights into the market through the fee chain.

Check Out More Reports

Global Active Pharmaceutical Ingredients Market: Report Forecast by 2032

Global On-Board Battery Charger Market: Report Forecast by 2032

Global Digital Transformation in Healthcare Market: Report Forecast by 2032

Global Panelized Modular Building Systems Market: Report Forecast by 2032

Global High Performance Computing Market: Report Forecast by 2032

#Peptide Therapeutics Market #Peptide Therapeutics Market 2024 #Global Peptide Therapeutics Market #Peptide Therapeutics Market outlook #Peptide Therapeutics Market Trend #Peptide Therapeutics Market Size & Share #Peptide Therapeutics Market Forecast #Peptide Therapeutics Market Demand #Peptide Therapeutics Market sales & price

0 notes

geethasingh · 1 year ago

Text

#Peptide Therapeutics Market #Peptide Therapeutics Market size #Peptide Therapeutics Market share #Peptide Therapeutics Market trends #Peptide Therapeutics Market analysis #Peptide Therapeutics Market forecast #Peptide Therapeutics Market outlook

0 notes

dbmrmark · 4 days ago

Text

Peptide and Anticoagulant Drugs Market Revenue Forecast: Growth, Share, Value, Size,Insights, Industry Analsis and Forecast by 2032

"Peptide and Anticoagulant Drugs Market Size And Forecast by 2032

Global peptide and anticoagulant drugs market size was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.93 billion by 2032, with a CAGR of 6.10% during the forecast period of 2025 to 2032.

Demand for Peptide and Anticoagulant Drugs Market solutions continues to rise, driven by consumer preferences for enhanced efficiency, sustainability, and customization. This growth is underpinned by evolving technologies, innovative product offerings, and strategic collaborations among market leaders. The interplay of these factors creates a fertile ground for revenue generation and industry expansion.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-peptide-and-anticoagulant-drugs-market

Which are the top companies operating in the Peptide and Anticoagulant Drugs Market?

The Top 10 Companies in Peptide and Anticoagulant Drugs Market are leaders in their field, known for their strong market presence and innovative solutions. Their success is driven by their ability to adapt to market trends, invest in research and development, and meet customer needs effectively, making them key competitors in the Peptide and Anticoagulant Drugs Market.

**Segments**

- **Peptide Drugs Market**: The peptide drugs segment is experiencing significant growth due to the rising demand for targeted therapeutic solutions with minimal side effects. Peptide drugs offer advantages such as high specificity, efficacy, and safety, driving their adoption in various disease treatments. With advancements in biotechnology and increasing R&D activities, the peptide drugs market is expected to witness continuous expansion.

- **Anticoagulant Drugs Market**: Anticoagulant drugs play a crucial role in preventing blood clot formation and reducing the risk of cardiovascular diseases. The market for anticoagulant drugs is driven by the growing prevalence of thrombotic disorders and the aging population. Factors such as lifestyle changes leading to an increase in lifestyle-related diseases further contribute to the demand for anticoagulant drugs.

**Market Players**

- **Amgen Inc.**: Amgen is a key player in the global peptide and anticoagulant drugs market, offering a diverse portfolio of innovative therapies. The company's strong focus on research and development has enabled it to introduce novel peptide-based drugs and anticoagulants.

- **Bristol-Myers Squibb Company**: Bristol-Myers Squibb is another prominent player in the market, known for its wide range of anticoagulant medications. The company's strategic collaborations and acquisitions have bolstered its position in the global market, ensuring a steady pipeline of new products.

- **Teva Pharmaceutical Industries Ltd.**: Teva Pharmaceutical Industries is a leading player in the peptide and anticoagulant drugs market, specializing in generic and specialty pharmaceuticals. The company's commitment to innovation and affordable healthcare solutions has contributed to its significant market presence.

- **Pfizer Inc.**: Pfizer is a major pharmaceutical company that offers a variety of peptide-based drugs and anticoagulants. The company's strong global presence and continual investment in research drive its growth in the competitive market landscape.

In conclusion, the global peptide and anticoagulant drugs market is witnessing robust growth, driven by factors such as increasing prevalence of chronic diseases, advancements in healthcare technology, and the rising geriatric population. Key market players are investing in research and development to introduce novel therapies and expand their product portfolios, further fueling market growth.

https://www.databridgemarketresearch.com/reports/global-peptide-and-anticoagulant-drugs-marketThe global peptide and anticoagulant drugs market continues to evolve, influenced by a combination of factors that shape the industry landscape. One significant trend is the increasing focus on personalized medicine, where targeted therapeutic solutions like peptide drugs are gaining traction due to their high specificity and safety profiles. This shift towards precision medicine is driven by advancements in biotechnology and genetics, enabling healthcare providers to tailor treatment approaches to individual patients' genetic makeup and unique characteristics.

Moreover, the rising prevalence of chronic diseases, including cardiovascular disorders and thrombotic conditions, is fueling demand for anticoagulant drugs across various demographics. Lifestyle changes, such as sedentary behaviors and unhealthy dietary habits, contribute to the escalating incidence of cardiovascular diseases, underscoring the importance of anticoagulant medications in managing and preventing these health issues. As the global population continues to age, the need for effective anticoagulation therapy remains a critical aspect of healthcare management, driving growth in this market segment.

Market dynamics are further influenced by the strategic maneuvers of key players such as Amgen Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., and Pfizer Inc. These industry stalwarts are not only expanding their product portfolios through research and development efforts but also leveraging partnerships, acquisitions, and collaborations to stay competitive in the market. By forging alliances with biotechnology firms, academic institutions, and smaller pharmaceutical companies, these players can access innovative technologies, novel drug candidates, and specialized expertise to drive innovation and enhance market presence.

In terms of regulatory landscape, stringent guidelines and approval processes govern the development, manufacturing, and commercialization of peptide and anticoagulant drugs. Regulatory bodies worldwide, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe, play a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products entering the market. Compliance with regulatory standards is imperative for market players to navigate complex approval pathways and bring new therapies to patients in a timely manner.

Looking ahead, the global peptide and anticoagulant drugs market is poised for continued growth and innovation, driven by a convergence of scientific advancements, demographic trends, and market dynamics. As research and development efforts yield novel treatment options and personalized medicine approaches gain prominence, the industry landscape is expected to evolve, offering new opportunities and challenges for market players and stakeholders alike. Staying abreast of market trends, technological innovations, and regulatory developments will be paramount for companies seeking sustainable growth and competitive advantage in this dynamic pharmaceutical sector.**Segments**

Global Peptide and Anticoagulant Drugs Market, By Low Molecular Weight Heparin Type (Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux), Type (Hormonal, Antibiotic, ACE Inhibitor, Antifungal, Others), Indication (Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032

The global peptide and anticoagulant drugs market is expected to witness substantial growth over the forecast period due to several factors. The increasing prevalence of chronic diseases such as diabetes, infectious diseases, cancer, and cardiovascular disorders is driving the demand for effective therapeutic solutions like peptide drugs and anticoagulants. The focus on personalized medicine and precision healthcare is propelling the adoption of targeted therapies with high specificity and safety profiles. Moreover, advancements in biotechnology, genetics, and healthcare technology are further accelerating market growth by enabling the development of innovative treatment options tailored to individual patient needs.

The market players in the global peptide and anticoagulant drugs sector play a crucial role in driving industry dynamics and shaping market trends. Notable companies such as F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Allergan, AstraZeneca, Johnson & Johnson Private Limited, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Eisai Co., Ltd., Bristol-Myers Squibb Company, Bayer AG, DAIICHI SANKYO COMPANY, LIMITED, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., and Aspen Holdings are key players driving innovation, research, and market expansion. These companies are actively involved in research and development activities, strategic collaborations, and acquisitions to broaden their product portfolios and strengthen their market presence, thus contributing to the overall growth of the global peptide and anticoagulant drugs market.

In conclusion, the global peptide and anticoagulant drugs market are poised for significant advancement and evolution in the coming years, fueled by increasing disease prevalence, technological advancements, and a growing emphasis on personalized healthcare. Market players' strategic initiatives and regulatory compliance will be instrumental in shaping the industry landscape and meeting the evolving needs of healthcare consumers worldwide. The market outlook remains positive, with opportunities for growth and innovation driving the development of novel therapies and treatment approaches for various medical conditions.

Explore Further Details about This Research Peptide and Anticoagulant Drugs Market Report https://www.databridgemarketresearch.com/reports/global-peptide-and-anticoagulant-drugs-market

Key Insights from the Global Peptide and Anticoagulant Drugs Market :

Comprehensive Market Overview: The Peptide and Anticoagulant Drugs Market is experiencing significant growth, driven by technological advancements and increasing global demand.

Industry Trends and Projections: Trends like automation and sustainability are shaping the market, with projections indicating continued growth over the next few years.

Emerging Opportunities: There are emerging opportunities in green technologies, digital solutions, and under-served regional markets.

Focus on R&D: Companies are investing heavily in R&D to innovate in areas such as AI, IoT, and sustainable product development.

Leading Player Profiles: Key players like Company A and Company B lead the market through their strong product offerings and global presence.

Market Composition: The market is fragmented, with a mix of established players and emerging startups targeting various niches.

Revenue Growth: The Peptide and Anticoagulant Drugs Market is seeing steady revenue growth, fueled by both consumer and commercial demand.

Commercial Opportunities: Key commercial opportunities include expanding into emerging regions, digital transformation, and forming strategic partnerships.

Find Country based languages on reports:

https://www.databridgemarketresearch.com/jp/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/zh/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/ar/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/pt/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/de/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/fr/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/es/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/ko/reports/global-peptide-and-anticoagulant-drugs-markethttps://www.databridgemarketresearch.com/ru/reports/global-peptide-and-anticoagulant-drugs-market

Data Bridge Market Research:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 975

Email:- [email protected]"

0 notes

global-research-report · 21 days ago

Text

Peptide Therapeutics: Market Dynamics, Challenges, and Emerging Trends

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights

By application, cancer held the second-largest revenue share in 2023 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment

The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class

Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production

By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth

North America held the largest share in terms of revenue in 2023 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives

Peptide Therapeutics Market Segmentation

Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region

Peptide Therapeutics Application Outlook (Revenue, USD Billion, 2018 - 2030)

Cancer

Metabolic Disorders

Cardiovascular Disorders

Respiratory Disorders

Gastrointestinal Disorders

Infectious Diseases

Pain

Dermatological Disorders

Neurological Disorders

Renal Disorders

Others

Peptide Therapeutics Type Outlook (Revenue, USD Billion, 2018 - 2030)

Generic

Innovative

Peptide Therapeutics Type of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)

In-house

Outsourced

Peptide Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

Parenteral Route

Oral Route

Pulmonary

Mucosal

Others

Peptide Therapeutics Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)

Solid Phase Peptide Synthesis (SPPS)

Liquid Phase Peptide Synthesis (LPPS)

Hybrid Technology

Peptide Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

Canada

Europe

Germany

France

Spain

Italy

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

UAE

Saudi Arabia

Kuwait

List of Key Players

Eli Lilly and Company

Pfizer Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

AstraZeneca

Teva Pharmaceutical Industries Ltd.

Sanofi

Hoffmann-La Roche Ltd

Novartis AG

Novo Nordisk A/S

GlaxoSmithKline plc.

Ironwood Pharmaceuticals, Inc.

Radius Health, Inc.

Ipsen Pharma

Order a free sample PDF of the Peptide Therapeutics Market Intelligence Study, published by Grand View Research.

#Peptide Therapeutics Market

0 notes

nithishkumble · 2 months ago

Text

Neuroendocrine Tumor Treatment Market

Neuroendocrine Tumour Treatment Market Size, Share, Trends: Novartis AG Leads

Personalised medicine approaches gain traction in NET treatment strategies

Market Overview:

The neuroendocrine tumour treatment market is expected to develop at a 10.2% CAGR from 2024 to 2031. The market is predicted to grow to XX USD by 2024 and YY USD by 2031. North America dominates the market, with significant indicators like rising incidence rates and advances in targeted therapy. The market is expanding rapidly due to increased awareness, improved diagnostic procedures, and the development of new treatment options.

DOWNLOAD FREE SAMPLE

Market Trends:

The therapy landscape for neuroendocrine tumours (NETs) is shifting dramatically towards personalised medicine. This method customises therapy for individual patients based on their genetic profiles, tumour features, and biomarkers. Molecular profiling approaches are increasingly being utilised to detect specific genetic changes in NETs, enabling more targeted and effective treatments. For example, the discovery of somatostatin receptor expression in NETs prompted the creation of peptide receptor radionuclide therapy (PRRT), which has demonstrated encouraging outcomes in clinical trials. Furthermore, circulating tumour DNA (ctDNA) analysis is emerging as a non-invasive technique of monitoring therapy response and disease progression, allowing for real-time modifications to treatment programs. This shift towards personalised medicine is expected to spur innovation in NET treatments, improve patient outcomes, and potentially lower healthcare expenditures associated with unsuccessful therapy.

Market Segmentation:

Targeted therapy dominates the treatment type segment, driven by its efficacy and reduced side effects compared to traditional chemotherapy. Targeted therapy has emerged as the dominant sector in the neuroendocrine tumour treatment industry, accounting for around YY% of the market in 2024. This dominance is due to the great specificity and efficacy of targeted medicines in treating NETs, which leads to better patient outcomes and fewer adverse effects than traditional chemotherapy. The clinical success of targeted treatments such as everolimus and sunitinib has resulted in their widespread use in NET therapy protocols.

Recent advances in targeted therapy for NETs have strengthened its market position. For example, in 2021, the United States Food and Drug Administration (FDA) approved surufatinib for the treatment of pancreatic and extra-pancreatic NETs, expanding patients' access to targeted medicines. This approval was based on two Phase III clinical trials that found significant increases in progression-free survival over placebo.

Market Key Players:

Novartis AG

Ipsen S.A.

Pfizer Inc.

Advanced Accelerator Applications (a Novartis company)

Hutchison China MediTech Limited

Tarveda Therapeutics

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market insights #market research #market trends

0 notes

hariganesh858 · 2 months ago

Text

Migraine Drugs Market

Migraine Drugs Market Size, Share, Trends: Allergan plc (AbbVie) Leads

Rising Adoption of Preventive Treatments Reshapes Therapeutic Landscape

Market Overview:

The global Migraine Drugs Market is projected to grow at a robust CAGR of 8.5% from 2024 to 2031, reaching a value of USD YY billion by 2031. North America currently dominates the market, accounting for approximately 45% of the global share. Key metrics driving this growth include the increasing prevalence of migraine disorders, growing awareness of treatment options, and rising demand for novel and more effective therapies. Advances in drug research, particularly in the field of targeted therapy, are transforming migraine treatment. The emergence of new pharmacological classes, such as calcitonin gene-related peptide (CGRP) antagonists, is driving market growth, alongside an increased emphasis on personalized therapy and the development of combination medications.

DOWNLOAD FREE SAMPLE

Market Trends:

A significant trend is the rising adoption of preventive migraine treatments, reshaping the therapeutic landscape. Patients and healthcare providers are increasingly focusing on proactive management of migraine disorders, seeking ways to reduce the frequency and severity of episodes. The growing use of CGRP antagonists and other innovative preventive drugs is particularly notable. The development of digital health technologies and wearable devices is also creating new opportunities for migraine prevention and management, offering a comprehensive approach to migraine care.

Market Segmentation:

The CGRP Antagonists segment emerges as a rapidly growing segment in the Migraine Drugs Market. This new class of medications has transformed migraine treatment by providing a more tailored strategy to preventing and treating migraine attacks. The segment's expansion is fueled by the remarkable efficacy of these medications, their innovative mechanism of action, and the significant unmet demand in migraine care. Clinical data showing the efficacy of CGRP Antagonists has contributed to their rapid growth, with many patients reporting improved quality of life and reduced side effects compared to traditional migraine therapies.

Market Key Players:

Leading players in the Migraine Drugs Market include Allergan plc (AbbVie), Amgen Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd., Biohaven Pharmaceutical Holding Company Ltd., Pfizer Inc., GlaxoSmithKline plc, Lundbeck A/S, and Johnson & Johnson. These key players focus on drug discovery innovation, treatment option expansion, and strategic acquisitions to enhance their product ranges and geographic reach.

Name: Hari Krishna

Email us: [email protected]

Website: https://aurorawaveintellects.com/

#market research #market insights #market trends

0 notes

jameswilliam4u · 2 months ago

Text

Global Peptide Therapeutics Market Trends, Outlook, Growth, Share, Size & Forecast | 2024 - 2032

The global peptide therapeutics market is set to experience substantial growth in the coming years, driven by advancements in peptide synthesis technologies and the increasing application of peptides in various therapeutic fields, such as oncology, diabetes, and cardiovascular diseases. As of 2023, the peptide therapeutics market value stood at USD 36.1 billion, and it is anticipated to grow at a compound annual growth rate (CAGR) of 7.6% between 2024 and 2032. By the end of the forecast period, the market size is expected to reach approximately USD 69.9 billion.

Peptide therapeutics, often regarded as the future of medicine, offer advantages over traditional small molecule drugs, including higher specificity, fewer side effects, and the ability to target a broader range of diseases. With innovations in peptide synthesis technologies and an increasing pipeline of peptide-based drugs, the global market is witnessing rapid growth. This post delves into the segments, key players, market trends, growth drivers, and market outlook for peptide therapeutics, along with an analysis of the COVID-19 impact on the industry.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/peptide-therapeutics-market/requestsample

Key Market Segments

The global peptide therapeutics market is highly segmented based on several factors, including product type, therapeutic application, route of administration, and region. Below is a breakdown of these segments:

1. By Product Type

Generic Peptides: These are often bioequivalent to branded peptide drugs and account for a significant share of the market due to their affordability and availability in large volumes.

Innovative Peptides: These are newly developed peptide-based drugs that offer higher specificity and efficacy in treating various diseases. With increasing R&D activities, the demand for innovative peptide therapeutics is expected to rise.

2. By Therapeutic Application

Peptide therapeutics are widely used in the treatment of various diseases. Some of the prominent therapeutic applications include:

Cancer: Peptides like somatostatin analogs and monoclonal antibody-based peptides have shown promise in targeting cancer cells.

Diabetes: Insulin peptides and glucagon-like peptides (GLP-1) are used for treating diabetes, a condition that is rising globally.

Cardiovascular Disorders: Peptide drugs for cardiovascular disease management, like B-type natriuretic peptide (BNP), are gaining traction.

Endocrine Disorders: Peptides for hormonal disorders, including pituitary-related diseases, are widely used.

Others: This includes areas such as central nervous system disorders, respiratory diseases, and inflammatory conditions.

3. By Route of Administration

Injectable: The injectable segment holds a dominant market share due to the established use of peptide therapeutics through subcutaneous injections and intravenous administration.

Oral: Oral peptide therapeutics are gaining traction due to patient preference for non-injectable forms. However, challenges remain regarding the stability of peptides in the gastrointestinal tract.

Nasal: Some peptides are administered nasally, especially for conditions affecting the central nervous system.

4. By Region

North America: The largest market share is held by North America, driven by advanced healthcare infrastructure, high healthcare spending, and the presence of leading pharmaceutical companies.

Europe: Europe is also a major player, especially with the growing adoption of peptide therapeutics for oncology and diabetes treatments.

Asia Pacific: The market in the Asia Pacific is growing rapidly, with countries like China, Japan, and India emerging as key hubs for peptide-based drug development.

Latin America & Middle East: Both these regions are witnessing steady growth due to improved healthcare access and awareness about peptide therapeutics.

Market Trends

Several key trends are shaping the global peptide therapeutics market:

1. Advancements in Peptide Synthesis Technologies

With continuous advancements in peptide synthesis technologies, such as solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), the production of high-quality peptides at scale has become more efficient and cost-effective. This is accelerating the development and commercialization of new peptide drugs.

2. Increasing Investment in R&D

The growing number of clinical trials and the focus on developing novel peptide-based therapeutics for a wide range of diseases is a significant trend. Biopharmaceutical companies are investing heavily in R&D to bring innovative peptide therapeutics to market. Advances in peptide engineering, drug delivery systems, and peptide formulations are also driving market growth.

3. Emerging Applications of Peptides in Cancer Treatment

Peptides are showing promise as both targeted therapies and carriers for chemotherapeutic agents in cancer treatment. Peptide-based vaccines, immunotherapy, and targeted peptide-drug conjugates (PDCs) are making strides in oncology, offering hope for more effective and less toxic cancer therapies.

4. Personalized Medicine

Personalized or precision medicine is becoming a key driver for the growth of peptide therapeutics. Peptide biomarkers and tailored peptide therapies are expected to offer more specific treatments for individual patients based on genetic and molecular profiling.

5. Development of Oral Peptide Drugs

The oral administration of peptides is a game-changer, offering improved patient compliance compared to injectable therapies. Though peptide stability in the gastrointestinal tract remains a challenge, advancements in formulation technology are enabling the development of oral peptide drugs, making them more patient-friendly.

Growth Drivers

1. Rising Incidence of Chronic Diseases

The growing burden of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and endocrine disorders, is driving the demand for peptide therapeutics. These diseases require long-term management, and peptides offer targeted and effective solutions.

2. Increasing Healthcare Expenditure

Rising healthcare expenditure in developed regions like North America and Europe is fostering the growth of the peptide therapeutics market. Governments and healthcare systems are increasingly investing in advanced treatments and therapies, including peptide-based drugs.

3. Aging Population

The global aging population is a critical driver for the peptide therapeutics market. Older adults are more susceptible to chronic diseases, and peptides offer an effective treatment for managing these conditions.

4. Regulatory Approvals and Market Expansion

The approval of new peptide-based therapeutics by regulatory agencies like the FDA and EMA is boosting market growth. As more peptides are approved for clinical use, their availability expands, and their adoption increases globally.

Key Players in the Peptide Therapeutics Market

Several major pharmaceutical and biotechnology companies dominate the peptide therapeutics market. These include:

Novo Nordisk: A leader in diabetes treatment, Novo Nordisk’s insulin peptides and GLP-1 receptor agonists like semaglutide are highly popular in the global market.

Ipsen: Ipsen is well-known for its peptide-based therapies in oncology, particularly for treating neuroendocrine tumours with somatostatin analogs.

Ferring Pharmaceuticals: Ferring is focused on peptide-based therapies for reproductive health and endocrinology.

Bachem AG: As a major player in the peptide synthesis and manufacturing sector, Bachem supplies the raw materials for peptide therapeutics and develops innovative peptide-based drugs.

Amgen: Amgen is developing several peptide-based therapies, particularly for cancer and metabolic diseases.

Sanofi: Sanofi is focusing on peptide-based treatments for diabetes and cardiovascular disorders, with liraglutide being a notable product in their portfolio.

Other prominent players in the peptide therapeutics space include Merck & Co., Inc., Teva Pharmaceuticals, AstraZeneca, and Novartis.

COVID-19 Impact on the Peptide Therapeutics Market

1. Disruptions in the Supply Chain

The COVID-19 pandemic caused significant disruptions in the global supply chain, including delays in the production and distribution of peptide-based therapeutics. However, as countries gradually recovered, the industry is now returning to pre-pandemic levels of production and distribution.

2. Increased Focus on Immunotherapies

The pandemic increased interest in peptide-based vaccines and immunotherapies to combat infectious diseases like COVID-19. The development of mRNA and peptide-based vaccines accelerated, potentially leading to a long-term increase in demand for peptide therapeutics.

3. Delayed Clinical Trials

Many clinical trials for peptide-based drugs were delayed during the pandemic due to restrictions on clinical visits and patient participation. However, as the world adapts to post-pandemic conditions, these trials are resuming, and the development of new peptide therapies is expected to progress.

Market Outlook and Future Trends

1. Continued Growth of the Market

The global peptide therapeutics market is expected to continue growing at a CAGR of 7.6% from 2024 to 2032. The development of new peptide drugs, especially in oncology and metabolic diseases, will contribute significantly to this growth.

2. Technological Advancements in Peptide Synthesis

As peptide synthesis technologies advance, the cost of production will decrease, making peptide therapeutics more accessible to a broader patient base. This will drive their adoption in emerging markets where healthcare access is improving.

3. Increasing Focus on Personalized Medicine

With the rise of genomic data, personalized medicine, and tailored peptide therapies will become a major growth avenue for the market. Peptides will be used to develop therapies that are specific to individual genetic profiles, leading to better patient outcomes.

FAQs

1. What are peptide therapeutics?

Peptide therapeutics are drugs made from short chains of amino acids (peptides) that are used to treat various diseases, including cancer, diabetes, and cardiovascular disorders.

2. What are the main therapeutic applications of peptides?

Peptides are widely used in oncology, diabetes, cardiovascular diseases, and endocrine disorders, among other therapeutic areas.

3. What are the growth drivers for the peptide therapeutics market?

Key drivers include the rising incidence of chronic diseases, advancements in peptide synthesis technologies, and increasing healthcare expenditure.

4. Who are the leading companies in the peptide therapeutics market?

Key players include Novo Nordisk, Ipsen, Ferring Pharmaceuticals, Bachem AG, Amgen, and Sanofi, among others.

5. How has COVID-19 impacted the peptide therapeutics market?

The pandemic disrupted supply chains and delayed clinical trials, but it also accelerated the development of peptide-based vaccines and therapies.

6. What is the future outlook for the peptide therapeutics market?

The market is expected to grow at a CAGR of 7.6% from 2024 to 2032, driven by advances in technology and increasing applications in various therapeutic areas.

Related Trending Related

https://www.expertmarketresearch.com/reports/silver-wound-dressing-markethttps://www.expertmarketresearch.com/reports/ischemic-heart-disease-drugs-markethttps://www.expertmarketresearch.com/clinical-trials/type-2-diabetes-drug-pipeline-analysis

#healthcare #market #peptides

0 notes

prabhugikwad1987 · 3 months ago

Text

0 notes

latestmarketresearchnews · 3 months ago

Text

Aptamers Industry 2030 Size, Share, Business Growth, Demand and Applications

The global aptamers market was valued at USD 1.94 billion in 2022 and is projected to grow at a significant compound annual growth rate (CAGR) of 24.54% from 2023 to 2030. Aptamers have garnered attention due to recent advancements in their generation, purification, and ability to effectively target and kill specific cells, which make them a powerful tool in therapeutic development.

The COVID-19 pandemic has presented unique challenges in the field of treatment due to the virus's high mutation rate. Currently, there are no fully effective treatments specifically targeting COVID-19 across all its variants. However, aptamers, particularly nucleic acid-based and peptide aptamers, have shown promise as a potential approach to combat COVID-19. The heightened focus on biotechnological solutions for COVID-19 treatment has spurred government and private sector initiatives to accelerate R&D in this area.

One example of government support is a contract awarded in September 2020 by the Department of Community & Economic Development, which allocated USD 320,000 to Aptagen LLC to support the research and development of a novel COVID-19 treatment using aptamers. This financial support aims to foster innovation in developing therapeutic solutions using aptamer technology.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

High Prevalence of Chronic Diseases: Rising rates of chronic illnesses such as cancer, cardiovascular diseases, and neurological disorders have fueled the demand for targeted therapies, boosting interest in aptamer-based treatments.

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

An example of North America’s commitment to aptamer R&D is seen in Noxxon Pharma's announcement in April 2022. The company presented the results of its NOX-A12 GLORIA trial for treating brain cancer at the American Society of Clinical Oncology annual meeting, underscoring the region's significant advancements in aptamer-based therapies.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Approval of New Aptamer-Based Products: Regulatory approvals of aptamer-based products are accelerating market expansion. For instance, Achiko AG entered an agreement in April 2020 with the Pengurus Wilayah Nahdlatul Ulama DKI, a prominent Islamic association in Indonesia, to promote its COVID-19 diagnostic kit AptameX.

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

The collaboration between Achiko AG and Pengurus Wilayah Nahdlatul Ulama DKI in Indonesia highlights the potential for aptamer-based products in diagnostic applications. This organization, which has around 90 million members, offers a significant market for innovative diagnostic tools, particularly as they address the ongoing COVID-19 pandemic.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

For instance, in January 2023, Aptamer Group announced a collaboration with BaseCure Therapeutics to develop Optimer-targeted therapies. Optimer technology is designed to enhance aptamer-targeted therapeutics, allowing for more precise drug delivery to target cells. This collaboration demonstrates the potential for aptamers in therapeutic applications and reflects the ongoing trend of partnerships within the industry aimed at driving innovation and broadening the use of aptamers in medical treatments.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

#Aptamers Market Research #Aptamers Market Forecast #Aptamers Market Overview

0 notes

researchreportinsight · 3 months ago

Text

Aptamers Market Analysis by Application 2030

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Regional Insights:

North America Aptamers Market Trends

North America led the global aptamers market with a 44.48% share in 2022. This dominance can be attributed to several factors:

Robust Healthcare Infrastructure: North America's well-developed healthcare system supports advanced research in biotechnology and pharmaceuticals, facilitating the growth of the aptamers market.

Increased Interest in Aptamer R&D: Research laboratories and institutions in the U.S. and Canada are increasingly focusing on aptamer research to explore novel treatments and diagnostic tools.

Asia Pacific Aptamers Market Trends

The Asia Pacific region is expected to witness the fastest growth in the aptamers market, with a CAGR of 26.18% during the forecast period. This rapid growth is driven by factors such as:

Increased Healthcare Demand: As healthcare needs grow, Asia Pacific countries, particularly China, Japan, and India, are adopting advanced technologies and investing in biotechnology.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global plasma fractionation market size was estimated at USD 35.8 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030.

The global sickle cell anemia testing and screening market size was estimated at USD 425.7 million in 2024 and is projected to grow at a CAGR of 12.1% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading companies in the aptamers market are actively pursuing strategies to enhance their product offerings and expand their market presence. These strategies include:

Product Modification: Companies are refining their existing aptamer products to improve efficacy and applicability across various therapeutic areas.

New Product Approvals: Firms are seeking regulatory approvals for novel aptamer-based products to strengthen their market share.

Mergers and Acquisitions: Strategic mergers and acquisitions are helping companies expand their product portfolios and enter new regional markets.

Key Aptamers Companies:

SomaLogic

Aptamer Group

Aptadel Therapeutics

Base Pair Biotechnologies

Noxxon Pharma

Vivonics Inc.

Aptagen, LLC

TriLink Biotechnologies

Altermune LLC

AM Biotechnologies

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

#Aptamers Market Research #Aptamers Market Forecast #Aptamers Market Overview

0 notes

janetushar1 · 3 months ago

Text

Peptide Therapeutics Market to Hit $84.6 Billion by 2032

The global Peptide Therapeutics Market was valued at USD 48.2 Billion in 2024 and it is estimated to garner USD 84.6 Billion by 2032 with a registered CAGR of 7.3% during the forecast period 2024 to 2032.

The report throws light on the competitive scenario of the global Peptide Therapeutics Market to know the competition at global levels. Market experts also provided the outline of each leading player of the global Peptide Therapeutics Market for the market, considering the key aspects such as the areas of operation, production, and product portfolio. In addition, the companies in the report are studied based on vital factors such as company size, market share, market growth, revenue, production volume, and profit.

The global Peptide Therapeutics Market is fragmented with various key players. Some of the key players identified across the value chain of the global Peptide Therapeutics Market include Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca PLC (UK), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland) etc. Considering the increasing demand from global markets various new entries are expected in the Peptide Therapeutics Market at regional as well as global levels.

Download Peptide Therapeutics Market Sample Report PDF: https://www.vantagemarketresearch.com/peptide-therapeutics-market-2350/request-sample

Top Competitors:

Understanding the Industry's Growth, has released an Updated report on the Peptide Therapeutics Market. The report is mixed with crucial market insights that will support the clients to make the right business decisions. This research will help new players in the global Peptide Therapeutics Market to sort out and study market needs, market size, and competition. The report provides information on the supply and market situation, the competitive situation and the challenges to the market growth, the market opportunities, and the threats faced by the major players.

Regional Analysis

-North America [United States, Canada, Mexico]

-South America [Brazil, Argentina, Columbia, Chile, Peru]

-Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

-Middle East & Africa [GCC, North Africa, South Africa]

-Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

You Can Buy This Report From Here: https://www.vantagemarketresearch.com/buy-now/peptide-therapeutics-market-2350/0

Full Analysis Of The Peptide Therapeutics Market:

Key findings and recommendations point to vital progressive industry trends in the global Peptide Therapeutics Market, empowering players to improve effective long-term policies.

The report makes a full analysis of the factors driving the development of the market.

Analyzing the market opportunities for stakeholders by categorizing the high-growth divisions of the market.

Questions answered in the report

-Who are the top five players in the global Peptide Therapeutics Market?

-How will the global Peptide Therapeutics Market change in the next five years?

-Which product and application will take the lion's share of the global Peptide Therapeutics Market?

-What are the drivers and restraints of the global Peptide Therapeutics Market?

-Which regional market will show the highest growth?

-What will be the CAGR and size of the global Peptide Therapeutics Market during the forecast period?

Read Full Research Report with [TOC] @ https://www.vantagemarketresearch.com/industry-report/peptide-therapeutics-market-2350

Reasons to Purchase this Peptide Therapeutics Market Report:

-Analysis of the market outlook on current trends and SWOT analysis.

-The geographic and country level is designed to integrate the supply and demand organizations that drive industry growth.

-Peptide Therapeutics Industry dynamics along with market growth opportunities in the coming years.

-Peptide Therapeutics Market value (million USD) and volume (million units) data for each segment and sub-segment.

1 year consulting for analysts along with development data support in Excel. Competitive landscape including market share of major players along with various projects and strategies adopted by players in the last five years.

Market segmentation analysis including qualitative and quantitative analysis including the impact on financial and non-economic aspects.

Complete company profiles that include performance presentations, key financial overviews, current developments, SWOT analyzes and strategies used by major Peptide Therapeutics Market players.

Check Out More Reports

Global Artificial Intelligence in Healthcare Market: Report Forecast by 2032

Global Turbocharger Market: Report Forecast by 2032

Global Online Education/E-Learning Market: Report Forecast by 2032

Global Automotive Wiring Harness, Connector and Cable Market: Report Forecast by 2032

Global Virtual Cards Market: Report Forecast by 2032

0 notes

jayanthitbrc · 3 months ago

Text

Global Peptide And Oligonucleotide CDMO Market Analysis 2024: Size Forecast and Growth Prospects

The peptide and oligonucleotide cdmo global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Peptide And Oligonucleotide CDMO Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The peptide and oligonucleotide CDMO market size has grown rapidly in recent years. It will grow from $1.93 billion in 2023 to $2.16 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to a rise in demand for therapeutic agents, advancements in synthesis and manufacturing, personalized medicine trends, regulatory guidelines, and increased focus on antiviral peptides and mRNA vaccines highlighting the potential of oligonucleotides in vaccine development.

The peptide and oligonucleotide CDMO market size is expected to see rapid growth in the next few years. It will grow to $3.39 billion in 2028 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to the growing demand for personalized medicine, advancements in biotechnology, expanding applications, increasing outsourcing, and the growing burden of chronic diseases. Major trends in the forecast period include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Scope Of Peptide And Oligonucleotide CDMO MarketThe Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Peptide And Oligonucleotide CDMO Market Overview

Market Drivers -The growing adoption of personalized medicine is expected to propel the growth of the peptide and oligonucleotide CDMO markets going forward. Personalized medicine is an approach to healthcare that tailors medical decisions and treatments to individual characteristics, such as genetics, environment, and lifestyle. The growing adoption of personalized medicine is due to several factors such as advancements in genomic technologies, increased understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options tailored to individual patients' genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a crucial role in personalized medicine by producing customized therapeutic peptides and oligonucleotides tailored to individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the peptide and oligonucleotide CDMO market.

Market Trends - Major companies operating in the peptide and oligonucleotide CDMO market are focusing on developing strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), partnered with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide's cGMP manufacturing capacities and market access, along with Numaferm's expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is focused on jointly exploring the development of suitable peptide candidates with the goal of more sustainable production of peptide-based APIs.

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides 2) By Service Type: Contract Development, Contract Manufacturing, 3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications 4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Get an inside scoop of the peptide and oligonucleotide cdmo market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Regional Insights - North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Table of Contents 1. Executive Summary 2. Peptide And Oligonucleotide CDMO Market Report Structure 3. Peptide And Oligonucleotide CDMO Market Trends And Strategies 4. Peptide And Oligonucleotide CDMO Market – Macro Economic Scenario 5. Peptide And Oligonucleotide CDMO Market Size And Growth ….. 27. Peptide And Oligonucleotide CDMO Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

industrynewsupdates · 4 months ago

Text

Aptamers Market Size, Key Companies, Trends, Growth and Forecast Report, 2030

The global aptamers market size is expected to reach USD 10.88 billion by 2030, according to a new report by Grand View Research Inc. The market is expected to expand at a CAGR of 24.54% from 2023 to 2030. The growth of the market is attributed to the strong presence of product pipelines and their expected launch during the forecast period. Some of the products in the pipeline are E10030 (Fovista), ARC1905 (Zimura) by IVERIC Bio, Inc., AGRO100 by Antisoma Research Ltd, NOX-A12 (olaptesed pegol) & NOX-E36 (emapticap pegol) by NOXXON Pharma, and NU172 by ARCA Biopharma, Inc. AGRO100 completed the phase 1 clinical trial for multiple oncology indications such as non-small cell lung cancer, solid tumors, and renal cancer.

In addition, initiatives undertaken by regulatory agencies such as the U.S. FDA, Health Canada, EMA, COFEPRIS, MHRA, and CDSCO to support the research and development in the field of aptamers are projected to fuel market growth. For instance, in March 2020, IVERIC Bio, Inc. received Fast Track designation from the U.S. FDA for Zimura for the treatment of patients with GA secondary to age-related macular degeneration (AMD). Zimura is a chemically synthesized pegylated RNA aptamer, administered by intravitreal injection. It acts by inhibiting complement factor C5 which is responsible for the development of AMD.

Companies are studying aptamers for applications such as western blotting, ELISA, therapeutics, and flow cytometry. Custom aptamer selection is considered to be an important service offered by existing aptamer players to life sciences companies. Thrombin aptamers, cocaine aptamers, and theophylline aptamers are some of the most frequently used customized aptamers for research and development activities. Thus, the surge in numbers of biotech and pharma companies working on research related to aptamers and related technologies has opened up new avenues for the growth of this market.

Gather more insights about the market drivers, restrains and growth of the Aptamers Market

Detailed Segmentation:

Type Insights

Based on type, aptamers market is segmented into nucleic acid aptamers and peptide aptamers. Nucleic acid segment held the highest market share of 78.19% in 2022 and is expected to witness the highest growth during the forecast period. At present, many companies are investigating the mechanism of action of nucleic acid aptamers for the treatment of various disorders including age related muscular degeneration (AMD). For instance, in June 2021, the U.S. Food and Drug Administration (FDA) granted written agreement under Special Protocol Assessment (SPA) to IVERIC BIO (formerly known as Ophthotech Corporation) for the design of GATHER2 phase 3 clinical trial of Zimura for treatment of patients with GA secondary to AMD. This approval is expected to boost the segment growth.

Application Insights

Based on application, the aptamers market is segmented into diagnostics, therapeutics development, research and development, and others. The research & development segment held the highest market share of 31.38% in 2022. The growth of segment is attributed to rising demand for aptamers coupled with increasing research activities in this field have paved the way for aptamers demand in research and development field. There are various strategic initiatives undertaken by key players like collaborations, partnerships, & agreements for R&D of novel aptamers based diagnostic and therapeutic products. For instance, in June 2021, SomaLogic and Ixaka Ltd entered into a research collaboration with an aim to support the discovery and development of aptamers based bispecific therapeutics. This collaboration evaluates the safety and efficacy of antigen specific SOMAmer reagents. Such an initiative is expected to boost the segment growth.

Regional Insights

North America region dominated the aptamers market with a share of 44.48% in 2022. The rising prevalence of chronic diseases, strong healthcare infrastructure, and growing interest of research laboratories in aptamer field are some of the major factors for the dominance of the region. Furthermore, in April 2022, Noxxon Pharma announced that it will present top line result data for its NOX-A12 GLORIA trial in brain cancer at the 2022 American Society of Clinical Oncology annual meeting.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global live cell imaging market size was valued at USD 2.48 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2024 to 2030.

• The global market for cell-free protein expression reached a value of USD 267.4 million in 2023 and is projected to grow at a CAGR of 8.6% from 2024 to 2030.

Key Companies & Market Share Insights

Major players are adopting strategies such as modification in the existing product, approval of new products, and mergers & acquisitions for product enhancements and regional expansion to attain a greater market share. For instance, in January 2023, Aptamer Group collaborated with BaseCure Therapeutics for the development of Optimer-targeted therapies. Such initiatives can open new avenues of growth for applications of aptamers in therapeutics.

Some of the prominent players in the global aptamers market include:

• SomaLogic

• Aptamer Group

• Aptadel Therapeutics

• Base Pair Biotechnologies

• Noxxon Pharma

• Vivonics Inc.

• Aptagen, LLC

• TriLink Biotechnologies

• Altermune LLC

• AM Biotechnologies

Aptamers Market Segmentation

Grand View Research has segmented the global aptamers market on the basis of type, application, and region:

Aptamers Type Outlook (Revenue, USD Million; 2018 - 2030)

• Nucleic Acid Aptamer

• Peptide Aptamer

Aptamers Application Outlook (Revenue, USD Million; 2018 - 2030)

• Diagnostics

• Therapeutics

• Research & Development

• Others

Aptamers Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o UK

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• MEA

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the Aptamers Market Intelligence Study, published by Grand View Research.

#Aptamers Market #Aptamers Market size #Aptamers Market share #Aptamers Market Analysis #Aptamers Industry

0 notes

rupalic · 4 months ago

Text

Driving Efficiency with Specialty Enzymes: A Look at Technological Advancements

Specialty enzymes are specific proteins designed to catalyse biochemical reactions for specialized applications in various industries. These enzymes are tailored to meet the unique requirements of different industrial processes, enhancing efficiency, specificity, and performance. The global specialty enzymes market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5%.

Key Applications of Specialty Enzymes:

Food and Beverage Industry:

Baking: Enzymes like amylases and proteases improve dough handling and bread quality.

Dairy: Lactases break down lactose, aiding in the production of lactose-free products.

Brewing: Proteases and beta-glucanases improve filtration and clarity in beer production.

Pharmaceuticals:

Therapeutic Enzymes: Used to treat diseases such as enzyme replacement therapies for lysosomal storage disorders.

Diagnostic Enzymes: Enzymes like glucose oxidase are used in biosensors for blood glucose monitoring.

Biofuels:

Cellulases and Hemicellulases: Break down plant biomass into fermentable sugars for ethanol production.

Lipases: Enhance biodiesel production by breaking down fats and oils.

Textile Industry:

Amylases: Remove starch-based sizing agents from fabrics.

Cellulases: Provide a soft finish to fabrics and improve color brightness.

Agriculture:

Phytases: Improve the bioavailability of phosphorus in animal feed, enhancing nutrition.

Proteases: Enhance the digestibility of feed proteins for better animal growth.

Enzymes sourced from animals hold a significant specialty enzymes market share

Animal-derived enzymes are often preferred for their high specificity and efficiency in catalyzing biochemical reactions, which is essential in various specialized processes. Pancreatic enzymes, such as trypsin and chymotrypsin, are extensively used in drug formulation and the production of biologics. These enzymes facilitate the precise cleavage of peptide bonds, crucial for developing and manufacturing therapeutic proteins and peptides. Their specificity and activity levels make them indispensable in pharmaceutical applications, significantly contributing to their market share.

Moreover, animal-derived enzymes are essential in clinical diagnostics. For example, rennet, obtained from the stomachs of calves, is used in the coagulation process for cheese production, highlighting their importance in the food industry. In clinical settings, enzymes like lactase, derived from animal sources, are used in diagnostic kits to test for lactose intolerance, demonstrating their versatility and utility in both food processing and medical diagnostics.

A notable example of the significance of animal-sourced enzymes is the use of thrombin, derived from bovine sources, in surgical procedures. Thrombin is crucial for promoting blood clotting and is used in topical hemostatic agents to control bleeding during surgeries. The high efficacy and reliability of thrombin in medical applications underscore the importance of animal-derived enzymes in the specialty enzymes market.

Factors Driving the Specialty Enzymes Market Growth

Public funding and incentives for biotechnological research are critical drivers of growth and innovation in the specialty enzymes market. The EU’s Horizon Europe program, with a budget of USD 103.6 billion for 2021-2027, is focused on research and innovation, including biotechnology. This program supports projects aimed at developing advanced biotechnological processes and products. In the United States, the National Institutes of Health (NIH) allocated over USD 42.0 billion for biomedical research in 2022, with part of this funding directed towards biotechnology research, including the development of novel enzymes for medical and industrial applications.

In India, the Biotechnology Industry Research Assistance Council (BIRAC) plays a significant role in fostering innovation and growth within the specialty enzymes market. Established by the Department of Biotechnology (DBT), Government of India, BIRAC actively supports biotech startups and research institutions through various funding schemes. One of the key initiatives is the Biotechnology Ignition Grant (BIG) scheme, which provides early-stage funding to startups and entrepreneurs with innovative ideas in biotechnology. In July 2020, BIRAC allocated Rs. 50 crores (approximately USD 6.7 million) under the BIG scheme to support around 100 startups and entrepreneurs in the biotechnology sector. This funding aims to catalyze innovation, encourage entrepreneurship, and accelerate the development of novel enzyme-based solutions for various applications in biotechnology and pharmaceuticals. By providing financial support and fostering a conducive ecosystem for research and development, initiatives like BIRAC’s BIG scheme contribute significantly to the growth and competitiveness of the enzyme market in India.

Top Specialty Enzymes Companies

BRAIN Biotech AG (Germany)

Novozymes A/S (Denmark)

Codexis, Inc. (US)

Sanofi (France)

Merck KGaA (Germany)

Dyadic International Inc (US)

Advanced Enzyme Technologies (India)

Amano Enzyme Inc (Japan)

F. Hoffmann-La Roche Ltd (Switzerland)

New England Biolabs (US)

BBI Solutions (UK)

North America region to dominate the specialty enzymes industry during the forecast period.

North America holds the highest market share in the specialty enzymes market due to several key factors. The region is home to a robust pharmaceutical and biotechnology industry, characterized by significant investments in research and development. This investment landscape fosters innovation, leading to the development of advanced enzyme-based solutions. For instance, companies like Codexis, Inc. (US), are at the forefront of enzyme engineering, continuously developing new enzymes for pharmaceutical and industrial applications.

Moreover, the presence of well-established healthcare infrastructure and a high demand for diagnostic tools contribute to the market’s growth. Specialty enzymes are crucial in various diagnostic applications, including ELISA (Enzyme-Linked Immunosorbent Assay) tests, which are widely used in medical diagnostics. The increasing prevalence of chronic diseases such as cancer and diabetes in North America drives the demand for these advanced diagnostic tools, further propelling the specialty enzymes industry.

0 notes

creativeera · 4 months ago

Text

Chromatography Resins Market is driving Separation and Purification Processes

Chromatography resins help separate and purify biomolecules and are used extensively in pharmaceutical, food, and chemical separation processes. Chromatography resins are polymer beads that facilitate the separation, purification, and quantification of biomolecules like proteins, peptides, nucleic acids, and small molecules. The beads contain ligands that bind selectively to biomolecules based on their chemical or physical properties. Based on the ligand used, chromatography resins are available in different variants like ion-exchange resins, affinity resins, hydrophobic interaction resins, size-exclusion resins. When a sample mixture passes through the chromatography resin column, different biomolecules bind to the resin with varying affinity based on their characteristics and get separated. Pure components can then be collected by changing the conditions like pH or introducing an elution buffer. The Global Chromatography Resins Market is estimated to be valued at US$ 2.2 Billion in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024-2027.

Rapid growth in the pharmaceutical and biotechnology industries and increasing research on drug discovery and large molecule biosimilars have boosted the demand for effective separation techniques. Chromatography resins have become integral to the purification of antibodies, vaccines, hormones, enzymes, and other therapeutic proteins. Key Takeaways Key players operating in the chromatography resins market are Thermo Fisher Scientific Inc., WR Grace & Co., Merck KGaA, Bio-Rad Laboratories Inc., Tosoh Corporation, and Purolite Corporation. The booming biopharmaceutical industry is driving consistent demand for chromatography resins for large-scale downstream processing applications. Monoclonal antibody production alone requires huge volumes of varied chromatography resins. Global players are expanding their production capacities across Asia Pacific and Latin America to meet the growing requirements of the pharmaceutical industry in emerging markets and benefit from low-cost manufacturing opportunities. Several new production plants for chromatography resins have come up over the past five years in China, India, Brazil, and Mexico. Market key trends One of the key trends gaining traction in the Chromatography Resins Market Demand is the rising popularity of pre-packed chromatography columns. These plug-and-play columns containing the resin reduce preparation time and improve reproducibility. They are well-suited for process development activities and process characterization runs involving short cycle-times. Major resin manufacturers are focusing on developing advanced pre-packed columns with better flow dynamics and higher binding capacities.

Porter’s Analysis Threat of new entrants: Low capital requirements and established value chain restrict threats of new entrants in chromatography resins market.

Bargaining power of buyers: Large number of buyers and availability of substitutes increases buyers bargaining power.

Bargaining power of suppliers: Established suppliers and intellectual property rights limit buyers bargaining power.

Threat of new substitutes: Emerging technologies pose threat of substitution to chromatography resins.

Competitive rivalry: Large number of players compete on cost and quality leading to high competitive rivalry. Geographical Regions North America accounts for the largest share in chromatography resins market in terms of value owing to increasing R&D investment and growth of pharmaceutical industry. Asia Pacific is anticipated to be the fastest growing region during the forecast period due to growing pharmaceutical industry, outsourcing trends and increasing research activities in countries like India and China.

Get more insights on Chromatography Resins Market

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

#Coherent Market Insights #Chromatography Resins Market #Chromatography Resins #Purification Resins #Protein Purification #Ion Exchange Resins #Affinity Chromatography Resins #Gel Filtration Resins

0 notes